...
首页> 外文期刊>Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents >High-throughput virtual screening, identification and in vitro biological evaluation of novel inhibitors of signal transducer and activator of transcription 3
【24h】

High-throughput virtual screening, identification and in vitro biological evaluation of novel inhibitors of signal transducer and activator of transcription 3

机译:高通量虚拟筛选,鉴定和体外信号转导抑制剂和转录激活剂的体外生物学评估3

获取原文
获取原文并翻译 | 示例

摘要

Signal transducer and activator of transcription (STAT) family, encompassing protein molecules that function as a second messenger and transcription factor, are famously known to regulate a multitude of cellular processes including inflammation, cell proliferation, invasion, angiogenesis, metastasis and immune system homeostasis. STAT3 is one of the six members of a family of transcription factors. STAT3 has proved themselves to be interesting candidates for anticancer therapy as they are over-expressed in most cancer cells. Thus, we studied receptor-based molecular docking of STAT3 against natural compounds and further validations of lead molecules in an array of cancer cells. In the present study, we screened approximately 50,000 natural compounds from the IBS. All natural compounds were docked with the X-ray crystal structure of STAT3 (PDB; 1BG1) retrieved from the protein data bank by using Maestro 9.6 (Schrodinger Inc). First, we performed high-throughput virtual screening of IBS against the SH2 domain of STAT3. Further, best 20 compounds that possess minimal Gscore along with 85 natural compounds that had been reported in published literature as having anticancer properties were selected, and molecular docking was performed using the XP (extra precision) mode of GLIDE. We analyzed Gscore and protein-ligand interactions of top ranking compounds. It was discovered in this study, compounds CID252682, CID5281670 (Morin), CID5281672 (Myricetin), CID72277 (Epigallocatechol) and CID65064 (Epigallocatechin Gallate, EGCG) yielded the excellent dock score with the STAT3 concluded with the help of docking-free energy. Moreover, IBS STOCK1N-43090, STOCK1N-66505, STOCK1N-54303, STOCK1N-44634, STOCK1N-45027, STOCK1N-73784, STOCK1N-69597, STOCK1N-73062, STOCK1N-81915 and STOCK1N-70844 have better docking-free energy. Further, we chose EGCG and myricetin compounds, and their effect on biological activity such as cell proliferation, oxidative stress, colony formation, mRNA expression of STAT3, and cell number was reported after the 48 h treatments in cancer cell lines. EGCG and myricetin reduce the STAT3 mRNA expression confirmed by RTPCR. Moreover, EGCG and myricetin reduce cell proliferation and ROS generation after 48 h treatments. Interestingly, our result also indicates that the reduction in potential for colony formation enhances anti-metastasis activity of EGCG and myricetin. The information obtained from our study assisted us in drawing a more lucid picture regarding the existence STAT3 natural compounds inhibitor on diverse cancer cells.
机译:众所周知,信号转导子和转录激活子(STAT)家族包含充当第二信使和转录因子的蛋白质分子,可调节多种细胞过程,包括炎症,细胞增殖,侵袭,血管生成,转移和免疫系统稳态。 STAT3是转录因子家族的六个成员之一。 STAT3已被证明是抗癌治疗的有趣候选对象,因为它们在大多数癌细胞中都过度表达。因此,我们研究了STAT3对天然化合物的基于受体的分子对接,以及一系列癌细胞中铅分子的进一步验证。在本研究中,我们从IBS中筛选了约50,000种天然化合物。使用Maestro 9.6(Schrodinger Inc)从蛋白质数据库中检索到的所有天然化合物都与STAT3(PDB; 1BG1)的X射线晶体结构对接。首先,我们针对STAT3的SH2域进行了IBS的高通量虚拟筛选。此外,选择了具有最小Gscore的最佳20种化合物以及已发表文献中报道的具有抗癌特性的85种天然化合物,并使用GLIDE的XP(超精确)模式进行了分子对接。我们分析了顶级化合物的Gscore和蛋白质-配体相互作用。在这项研究中发现,化合物CID252682,CID5281670(莫林),CID5281672(杨梅素),CID72277(表没食子儿茶酚)和CID65064(表没食子儿茶素没食子酸酯,EGCG)产生了出色的停靠得分,其中STAT3依靠无停靠能量得出结论。此外,IBS STOCK1N-43090,STOCK1N-66505,STOCK1N-54303,STOCK1N-44634,STOCK1N-45027,STOCK1N-73784,STOCK1N-69597,STOCK1N-73062,STOCK1N-81915和STOCK1N-70844的对接性能更好。此外,我们选择了EGCG和杨梅素化合物,并在癌细胞系中治疗48小时后报道了它们对诸如细胞增殖,氧化应激,集落形成,STAT3的mRNA表达和细胞数量等生物学活性的影响。 EGCG和杨梅素降低RTPCR证实的STAT3 mRNA表达。此外,EGCG和杨梅素可减少48 h治疗后的细胞增殖和ROS生成。有趣的是,我们的结果还表明,菌落形成潜力的降低增强了EGCG和杨梅素的抗转移活性。从我们的研究中获得的信息有助于我们更清楚地了解各种癌细胞上是否存在STAT3天然化合物抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号